Cabaletta Bio director buys 4,405 CABA shares
Cabaletta Bio, Inc. director Catherine Bollard reported a purchase of 4,405 shares of the company’s common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Cabaletta Bio, Inc. director Catherine Bollard reported a purchase of 4,405 shares of the company’s common stock. The transaction took place on 01/21/2026 at a price of $2.2661 per share, according to a Form 4 insider trading report.
Following this open-market purchase, Bollard’s reported beneficial ownership increased to 5,405 shares, held directly. The filing indicates the transaction code "P," which denotes a purchase of non-derivative securities.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock | 4,405 | $2.2661 | $10K |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Cabaletta Bio (CABA) report for Catherine Bollard?
Is the Cabaletta Bio (CABA) insider transaction direct or indirect ownership?
What type of security was involved in this Cabaletta Bio (CABA) Form 4 filing?
What does transaction code "P" mean in the Cabaletta Bio (CABA) Form 4?
AI-generated analysis. How Rhea-AI works. Not financial advice.